4 Firms Lead Clinical Stage Atai For $3B Valuation In IPO
Mental health-focused biopharmaceutical atai had a strong Nasdaq debut Friday, as its stock price rose about 30%, giving the company a market valuation of nearly $3 billion following an upsized initial...To view the full article, register now.
Already a subscriber? Click here to view full article